Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.2 HKD | +0.45% | +24.86% | -4.74% |
04/06 | Akeso Expands Territory of License Agreement for Lung Cancer Drug | MT |
03/06 | Summit Therapeutics Inc. Expands License Territories for Ivonescimab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.74% | 487.19Cr | |
+16.73% | 12TCr | |
+13.04% | 11TCr | |
-5.80% | 2.48TCr | |
+1.69% | 2.25TCr | |
-10.09% | 1.83TCr | |
-40.52% | 1.63TCr | |
-14.00% | 1.53TCr | |
+1.18% | 1.41TCr | |
+24.18% | 1.17TCr |
- Stock Market
- Equities
- 9926 Stock
- News Akeso, Inc.
- Akeso : New Drug Application for Cancer Therapy Accepted in China